1. severe clinical condition (meeting one of the following criteria: a resting respiratory rate greater than 30 per minute, oxygen saturation below 93%, oxygenation index (oi) \< 300 mmhg (1 mmhg = 133.3 pa), respiratory failure, shock, and/or combined failure of other organs that required icu monitoring and treatment). 2. chronic liver and kidney disease and reaching end stage. (serum aspartate aminotransferase (ast) and serum alanine aminotransferase (alt) will be elevated over 5 times of normal upper range will excluded). (normal upper limit of serum ast = 40 units /l, alt = 56 units /l) 3. serum uric acid \>7.0 mg/dl in male and serum uric acid \>6.0 mg/dl in female will excluded 4. icu patient 5. previous history of allergic reactions to favipiravir. 6. pregnant or lactating women 7. women of a childbearing age with a positive pregnancy test. 8. miscarriage, or within 2 weeks after delivery 9. hypertensive patients, who are taking calcium channel blockers

1. severe clinical condition (meeting one of the following criteria: a resting respiratory rate greater than 30 per minute, oxygen saturation below 93%, oxygenation index (oi) \< 300 mmhg (1 mmhg = 133.3 pa), respiratory failure, shock, and/or combined failure of other organs that required icu monitoring and treatment). 2. chronic liver and kidney disease and reaching end stage. (serum aspartate aminotransferase (ast) and serum alanine aminotransferase (alt) will be elevated over 5 times of normal upper range will excluded). (normal upper limit of serum ast = 40 units /l, alt = 56 units /l) 3. serum uric acid \>7.0 mg/dl in male and serum uric acid \>6.0 mg/dl in female will excluded 4. icu patient 5. previous history of allergic reactions to favipiravir. 6. pregnant or lactating women 7. women of a childbearing age with a positive pregnancy test. 8. miscarriage, or within 2 weeks after delivery 9. hypertensive patients, who are taking calcium channel blockers

severe clinical condition (meeting one of the following criteria: a resting respiratory rate greater than 30 per minute, oxygen saturation below 93%, oxygenation index (oi) < 300 mmhg (1 mmhg = 133.3 pa), respiratory failure, shock, and/or combined failure of other organs that required icu monitoring and treatment). chronic liver and kidney disease and reaching end stage. (serum aspartate aminotransferase (ast) and serum alanine aminotransferase (alt) will be elevated over 5 times of normal upper range will excluded). (normal upper limit of serum ast = 40 units /l, alt = 56 units /l) serum uric acid >7.0 mg/dl in male and serum uric acid >6.0 mg/dl in female will excluded icu patient previous history of allergic reactions to favipiravir. pregnant or lactating women women of a childbearing age with a positive pregnancy test. miscarriage, or within 2 weeks after delivery hypertensive patients, who are taking calcium channel blockers

severe clinical condition (meeting one of the following criteria: a resting respiratory rate greater than 30 per minute, oxygen saturation below 93%, oxygenation index (oi) < 300 mmhg (1 mmhg = 133.3 pa), respiratory failure, shock, and/or combined failure of other organs that required icu monitoring and treatment). chronic liver and kidney disease and reaching end stage. (serum aspartate aminotransferase (ast) and serum alanine aminotransferase (alt) will be elevated over 5 times of normal upper range will excluded). (normal upper limit of serum ast = 40 units /l, alt = 56 units /l) serum uric acid >7.0 mg/dl in male and serum uric acid >6.0 mg/dl in female will excluded icu patient previous history of allergic reactions to favipiravir. pregnant or lactating women women of a childbearing age with a positive pregnancy test. miscarriage, or within 2 weeks after delivery hypertensive patients, who are taking calcium channel blockers

1. severe clinical condition (meeting one of the following criteria: a resting respiratory rate greater than 30 per minute, oxygen saturation below 93%, oxygenation index (oi) < 300 mmhg (1 mmhg = 133.3 pa), respiratory failure, shock, and/or combined failure of other organs that required icu monitoring and treatment). 2. chronic liver and kidney disease and reaching end stage. (serum aspartate aminotransferase (ast) and serum alanine aminotransferase (alt) will be elevated over 5 times of normal upper range will excluded). (normal upper limit of serum ast = 40 units /l, alt = 56 units /l) 3. serum uric acid >7.0 mg/dl in male and serum uric acid >6.0 mg/dl in female will excluded 4. icu patient 5. previous history of allergic reactions to favipiravir. 6. pregnant or lactating women 7. women of a childbearing age with a positive pregnancy test. 8. miscarriage, or within 2 weeks after delivery 9. hypertensive patients, who are taking calcium channel blockers

1. severe clinical condition (meeting one of the following criteria: a resting respiratory rate greater than 30 per minute, oxygen saturation below 93%, oxygenation index (oi) < 300 mmhg (1 mmhg = 133.3 pa), respiratory failure, shock, and/or combined failure of other organs that required icu monitoring and treatment). 2. chronic liver and kidney disease and reaching end stage. (serum aspartate aminotransferase (ast) and serum alanine aminotransferase (alt) will be elevated over 5 times of normal upper range will excluded). (normal upper limit of serum ast = 40 units /l, alt = 56 units /l) 3. serum uric acid >7.0 mg/dl in male and serum uric acid >6.0 mg/dl in female will excluded 4. icu patient 5. previous history of allergic reactions to favipiravir. 6. pregnant or lactating women 7. women of a childbearing age with a positive pregnancy test. 8. miscarriage, or within 2 weeks after delivery 9. hypertensive patients, who are taking calcium channel blockers